|Bid||36.10 x 1400|
|Ask||36.63 x 1800|
|Day's range||35.76 - 36.33|
|52-week range||27.88 - 40.97|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||14.35|
|Earnings date||27 Oct 2020|
|Forward dividend & yield||1.52 (4.19%)|
|Ex-dividend date||30 Jul 2020|
|1y target est||41.79|
The U.S. marked a grim milestone in the coronavirus pandemic, with more than 200,000 deaths reported Tuesday, even as optimism continues to rise over a vaccine.
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application(sNDA)for XALKORI® (crizotinib) for the treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. XALKORI received Breakthrough Therapy designation (BTD) for the ALK-positive ALCL indication in May 2018 and if approved, would be the first biomarker-driven therapy for this type of pediatric lymphoma. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is January 2020.
One way to maximize your potential returns is to invest in stocks that pay dividends. The two stocks listed here, Pfizer (NYSE: PFE) and Verizon (NYSE: VZ), not only still pay dividends, they've also been increasing them over the years. Healthcare giant Pfizer is an attractive investment for multiple reasons.